Project Grant R01CA297721
Award Date 8/15/25
Completion Date 7/31/30
Dollars Obligated $608K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $636,046 to the Weill Medical College of Cornell University to conduct research aimed at defining the oncogenic potential and therapeutic dependencies of PDAC-associated KRAS variants. The key products and services to be delivered under this 5-year award, which began on November 25, 2024, include: Deciphering how cell lineage impacts the neoplastic transformation and molecular...
- This Project Grant award of $435,827, provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research at New York University School of Medicine to investigate methods for enhancing the effectiveness of KRAS inhibitor cancer therapies. The research aims to identify synthetic lethal genetic interactions that could be leveraged to improve outcomes for patients with KRAS-mutated cancers, which are common in lung, colorectal, and pancreatic...
- This federal Project Grant award, funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research to mechanistically understand and modulate cytoskeletal regulation as a way to overcome innate resistance to KRAS inhibition in cancer. The $375,150 award, with a performance period from September 1, 2025 to August 31, 2030, was made to the University of California, San Francisco (UCSF). The research aims to study adaptive resistance mechanisms, including the...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $703,410.00 to New York University School of Medicine to conduct research on the adeno-to-squamous transition in non-small cell lung cancer. The research aims to identify chromatin regulators that drive this cellular adaptation, which enables resistance to targeted KRAS inhibitor therapy. The award began on January 16, 2025 and is scheduled to run through December 31, 2029....
- This federal Project Grant award of $205,700 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research at the Sloan-Kettering Institute for Cancer Research in New York aimed at understanding and overcoming rapid resistance to targeted therapies in colorectal cancer. The key objectives are to evaluate how intrinsic tumor features modulate the development of resistance to targeted therapies, and to test a novel combination approach to...
- This Project Grant award, valued at $411,152, was provided by the National Cancer Institute under the Cancer Treatment Research federal grant program (CFDA 93.395). The grant supports research at Duke University to identify and validate non-covalent interacting proteins of mutant KRAS inhibitors, which are critical for developing effective therapies for lung, pancreatic, and colorectal cancers driven by oncogenic KRAS mutations. The research aims to utilize mass spectrometry-based proteomics...
- The National Cancer Institute awarded a $269,280 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395) to Cold Spring Harbor Laboratory, a non-profit research institution. The grant supports the development of a novel targeted approach for K-RAS(G12C) mutation-driven cancers. The project aims to create prodrug molecules that can selectively degrade the K-RAS(G12C) protein and release cytotoxic polypharmaceuticals to concurrently target multiple pathways. The key...
- The federal Project Grant award of $472,730.00 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) is funding research at Weill Medical College of Cornell University to elucidate the role of the tumor suppressor KEAP1 in antitumor immunity for non-small cell lung cancer (NSCLC). The research aims to investigate how newly identified upregulated oncoproteins that are potential KEAP1 substrates contribute to the immune-evasive phenotype observed in KEAP1-mutant NSCLCs. The...
- This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $433,256 to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The funding supports research to identify novel targets and develop lead compounds to overcome resistance to KRAS inhibitors for lung, colon, and other cancers. The project leverages fragment-based chemoproteomics approaches to probe biological target...
- This $680,507 Project Grant was awarded on April 1, 2025 by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of California, San Francisco. The grant aims to elucidate mechanisms of cancer persister cell rewiring and identify druggable targets to eradicate persistence in KRAS-mutant non-small cell lung cancer. The key objectives are to: 1) illuminate signals that promote persistence in physiological contexts, 2) identify and validate targets that inhibit...